62,666
edits
Changes
no edit summary
|-
| 2016 (December) || || || Study || A study finds the {{w|rVSV-ZEBOV vaccine}} against {{w|Ebola virus disease}} to be 95-100% effective, making it the first proven vaccine against the disease.<ref name="TL-20161222">{{cite journal |vauthors=Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen JA, Kieny MP|display-authors=6 |title=Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) |journal = Lancet |volume = 389 |issue = 10068 |pages = 505–518 |year = 2017 |pmid = 28017403 |pmc = 5364328 |doi = 10.1016/S0140-6736(16)32621-6 }}</ref><ref name="CNN-2016122">{{cite news |last=Berlinger |first=Joshua |title=Ebola vaccine gives 100% protection, study finds |url=http://www.cnn.com/2016/12/22/health/ebola-vaccine-study/index.html |date=22 December 2016 |work=[[CNN]] |accessdate=25 April 2018}}</ref> ||
|-
| 2019 || January 14 || {{w|Tetanus}}, {{w|diphtheria}}, {{w|pertussis}} || Vaccine approval || "FDA approved expanded use of Sanofi's Adacel Tdap vaccine for a second dose in people ages 10 through 64 years of age."<ref>{{cite web |title=FDA Approves Expanded Use of Adacel® (Tdap) Vaccine for Repeat Vaccination |url=http://www.news.sanofi.us/2019-01-14-FDA-Approves-Expanded-Use-of-Adacel-R-Tdap-Vaccine-for-Repeat-Vaccination |website=news.sanofi.us |accessdate=1 June 2020}}</ref> ||
|-
| 2019 || January 23 || Influenza || Vaccine approval || "FDA approved use of the 0.5 mL dose of Sanofi's Fluzone Quadrivalent influenza vaccine to include children age 6 through 35 months."<ref>{{cite web |title=FDA approves use of 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) in children as young as 6 months of age |url=http://www.news.sanofi.us/2019-01-23-FDA-approves-use-of-0-5-mL-dose-of-Fluzone-R-Quadrivalent-influenza-vaccine-in-children-as-young-as-6-months-of-age |website=news.sanofi.us |accessdate=1 June 2020}}</ref> || {{w|United States}}
